Compugen (CGEN) Stock: Buy, Sell, or Hold?
CGEN - Compugen Ltd
$2.31
-0.03 (-1.28%)
▼
5d:
-2.94%
30d:
-12.17%
90d:
-2.12%
WAIT
LOW Confidence
Analysis Updated: Oct 2, 2026 12:00 AM ET
Earnings: Nov 09, 2026
Get Alerted When CGEN Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 MIXED SIGNALS: CGEN shows conflicting indicators. Wait for confirmation before entering.
📊 MIXED SIGNALS: CGEN shows conflicting indicators. Wait for confirmation before entering.
In-depth Analysis How we analyze
Valuation Analysis: CGEN is currently trading at $2.31, which is considered oversold relative to its 30-day fair value range of $2.36 to $2.61.
Technical Outlook: Technically, CGEN is showing sideways momentum. The price is currently testing key support at $2.30. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock scores a mixed 59/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. In the options market, Implied Volatility is low (7th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $4.60 (+99.1%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, CGEN is showing sideways momentum. The price is currently testing key support at $2.30. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock scores a mixed 59/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. In the options market, Implied Volatility is low (7th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $4.60 (+99.1%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$2.36 -
$2.61
Company Quality Score
47/100
(HOLD)
Options IV Signal
7th percentile
(LOW)
Volume Confirmation
HIGH
Confidence Score
86.2%
All Signals
- BULLISH: Price oversold vs 30-day range
- BULLISH: Options cheap (IV 7th percentile)
- NEUTRAL: Mixed technical signals (59/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 99.1% below Wall St target ($4.60)
- WARNING: Composite score 47/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$2.36 -
$2.61
Current vs Trading Range
OVERSOLD
Expected Move (7 Days)
±$0.16
(7.1%)
Support & Resistance Levels
Support Level
$2.30
Resistance Level
$2.50
Current Trend
Sideways
Technical data as of
Oct 2, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-6.30
Wall Street Target
$4.60
(+99.1%)
Revenue Growth (YoY)
107.0%
Profit Margin
47.6%
Share & Embed Analysis
Last updated: October 04, 2026 12:31 AM ET
Data refreshes hourly during market hours. Next update: 1:31 AM
Data refreshes hourly during market hours. Next update: 1:31 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is CGEN showing a specific setup today?
Insider Activity (6 Months)
0
Buys
3
Sells
Net
INSIDERS SELLING
Recent Transactions
Eran Ophir
SELL
5000 shares
2026-04-14
Zurit Levine
SELL
3125 shares
2026-04-10
Zurit Levine
SELL
5375 shares
2026-04-08
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ALNY
Alnylam Pharmaceuticals … |
STRONG BUY
30 analysts |
$371 | 49 HOLD |
|
ONC
BeiGene, Ltd. |
STRONG BUY
24 analysts |
$433 | 56 HOLD |
|
VRTX
Vertex Pharmaceuticals I… |
BUY
34 analysts |
$570 | 55 HOLD |
|
ASND
Ascendis Pharma AS |
STRONG BUY
16 analysts |
$310 | 66 BUY |
|
CLDX
Celldex Therapeutics Inc |
STRONG BUY
15 analysts |
$63 | 60 BUY |
